Abstract:OBJECTIVE:To investigate the dynamic quantitative changes in expression of hepatitis B virus (HBV) surface antigen (HBsAg) that occurs during the natural recovery course and the short-term antivirus treatment period of patients suffering from flares in chronic hepatitis B (CHB).METHODS:CHB patients presenting for treatment of flare-ups were randomly assigned to receive treatment with Entecavir antiviral (group A, n = 39) or to naturally resolve the acute condition (group B, n = 22). All patients MELD scores were calculated and HBsAg levels and HBV DNA loads were measured upon admission (baseline), at worst-condition stage, and end of treatment/flare-up (discharge). Pairwise comparisons of intergroup differences were made to evaluate the change in the three disease parameters over time in response to the management approach.RESULTS:The levels of HBsAg were not significantly different between the two groups at baseline, worst-condition stage and discharge (group A: (3.68+/-0.45), (3.84+/-0.19) and (3.69+/-0.58) log10 cut-off index (COI) respectively; group B: (3.59+/-0.54), (3.47+/-0.76) and (3.43+/-0.68) log10 COI respectively; all P more than 0.05). However, the HBV DNA loads were significantly lower in group A than in group B at the worst-condition stage and at discharge (all P less than 0.05). In group A, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant. Also in group A, the HBV DNA load showed a gradually decreasing trend over time (baseline more than worst-condition stage more than discharge, all P less than 0.05). No significant differences were observed over time in the HBsAg levels of group A. In group B, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant (P = 0.619). Also in group B, the HBV DNA loads were significantly higher at baseline and worst-condition stage than at discharge (P = 0.000 and P = 0.003 respectively), but the difference between baseline and worst-condition stage was not significant. Finally, no significant differences were observed over time in the HBsAg levels of group B.CONCLUSION:Natural recovery from an acute flare-up of CHB is not accompanied by a change in HBsAg levels. In addition, short-term antiviral treatment to resolve the flare-up has no influence on HBsAg level.

[Differential Clinical Diagnostic Parameters of Acute Hepatitis B and Flare of Chronic HBV Infection].

Analysis on Clinical Features and Immunity in Chronic Hepatitis B Virus Infected Patients with Low-Level Hbsag

Clinical Significance and Detection of IL-18 in the Chronic Patients with HBV Infection

[Relationship between the quantitative results of HBV DNA and HBV markers (HBV M) in population with low-level HBsAg].

[Dynamic Change of Hepatitis B Surface Antigen Expression in Chronic Hepatitis B Patients During the Natural Recovery Course and the Short-Term Antivirus Treatment].

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

Predictors of Inflammatory Activity in Treatment-Naive Hepatitis B E-Antigen-negative Patients with Chronic Hepatitis B Infection

Level Changes and Clinical Significance of Plasma IL-18,IP-10 in Patients with Chronic Hepatitis B During Antiviral Treatment

Clinical Diagnostic Value of Quantitative Hepatitis B Virus Core Antibody Test in Chronic Viral Hepatitis B

Changes of the peripheral Thelper cell cytokines of patients with chronic hepatitis B during antiviral treatment

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Correlation between plasma amino acid profiles and the various stages of hepatitis B infection

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease

Dynamics of HBV-DNA Level in Acute Hepatitis B

Quantitative Serum HBV Markers in Predicting Phases of Natural History of Chronic HBV Infection.

*Correspondence to: Chao Wu and Rui Huang, . ORCID: https://orcid.org/0000-0002-1657-010X (CW), https://orcid.org/0000-0002-3189-7960 (RH). Tel:+86-25-8310-5890 (CW),+86-25-8310-6666-20201 (RH), Fax:+86-25-8330-7115 (CW),+86-25-8330-7115 (RH), E-mail: dr.wu@ nju.edu.cn (CW), doctor_hr@126.com (RH)

Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection

Detection and Clinical Value of Blood IFN -Γ Receptor Level in Patients with Chronic Hepatitis B

High Expression of Interleukin-33/ST2 Predicts the Progression and Poor Prognosis in Chronic Hepatitis B Patients with Hepatic Flare

Evaluation on the correlation between HBV-DNA and serum HBV-LP of patients with hepatitis B and its clinical application

Characteristics of HBV Novel Serum Markers Across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients